Pan-cancer analysis of DDX31 as a promising predictor for clinical prognosis and immunotherapy response

Résumé fourni par la source

DEAD box polypeptide 31 (DDX31), a member of the Asp-Glu-Ala-Asp (DEAD) box RNA helicase family, has been implicated in the progression of various malignancies, including muscle-invasive bladder cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma. To elucidate the multifaceted roles of DDX31 in oncogenesis, we conducted a comprehensive pan-cancer analysis to investigate its prognostic significance, functional implications, and immune-related characteristics through deep data mining. Our findings revealed that DDX31 was significantly upregulated in the majority of tumor types. Furthermore, DDX31 expression demonstrated strong prognostic value across multiple cancer types. Notably, DDX31 levels showed a significant positive correlation with immunoregulators and immune checkpoints in pan-cancer analysis. Conversely, DDX31 expression was inversely associated with immune cell infiltration in most malignancies. Importantly, integrated bulk-RNA and single-cell sequencing analyses revealed that DDX31 expression negatively correlated with immune regulatory systems while positively associating with oncogenic signaling pathways involved in tumor initiation and progression. Additionally, DDX31 demonstrated considerable predictive value for immunotherapy response. To validate these findings, we confirmed that DDX31 was upregulated in hepatocellular carcinoma (HCC) and that CRISPR/Cas9-mediated DDX31 knockout significantly inhibited HCC cell proliferation. Collectively, our pan-cancer analysis suggested that DDX31 may serve as a potential prognostic biomarker and provided a theoretical foundation for the development of targeted therapies against DDX31 in cancer treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.